DARPA commercial solutions opening - embedded entrepreneur initiative
Active Definitive Contract Awarded Last action
- Contract number
- HR001126CE073
- Awardee
-
Repro-T Company UEI TQ2TYYVLY216
- Awarding agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Obligated
- $349,997
Award facts
- Opportunity
-
- DARPA's Commercial Solutions Opening (DCSO) for Commercial Strategy Solicitation · HR001125RE003 · Posted May 1, 2025
- Contract value 100% obligated
- $349,996.50 Current and potential, with all options
- Completion date 50% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- B541 Special Studies/Analysis- Defense
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 35 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Arlington, VA 22203, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $349,997 |
About this award
The Defense Advanced Research Projects Agency awarded a $349,996.50 definitive firm-fixed-price contract to Repro-T Company (Portal Biotechnologies division) for technology commercialization on May 4, 2026, under DARPA's Commercial Solutions Opening program without a set-aside.
The Embedded Entrepreneurship Initiative solicitation seeks to transition and commercialize innovative technologies derived from prior DARPA research and development programs into military and civilian capabilities. Eligible organizations must possess technology rights from earlier DARPA efforts. Evaluation criteria address potential contribution to DARPA's mission, commercialization readiness, and fair and reasonable pricing. The base effort runs twelve months with an optional twenty-four-month Minimum Viable Product development phase, concluding no later than May 3, 2027. Work is performed in Arlington, Virginia. Portal Biotechnologies develops high-throughput screening and intracellular delivery platforms, currently advancing a Galaxy system using mechanoporation-based technology for multiplexed intracellular biomolecule delivery in cell-based assays. The company holds a concurrent $7.879 million multiple-award Other Transaction IDV from DARPA issued June 1, 2025, under the BTO RBC Factory Program, structured outside the FAR framework under 10 U.S.C. 4022.
Quick answers
Who was awarded contract HR001126CE073?
HR001126CE073 was awarded to Repro-T Company by Defense Advanced Research Projects Agency (Department of Defense) on May 4, 2026.
How much is contract HR001126CE073 worth?
The government has obligated $349,997 on HR001126CE073.
Was contract HR001126CE073 competed?
The extent of competition for HR001126CE073 was competed under sap. The government received 35 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award